zunsemetinib   Click here for help

GtoPdb Ligand ID: 11681

Synonyms: ATI-450 | ATI450 | CDD-450 | CDD450
Compound class: Synthetic organic
Comment: We obtained the chemical structure for zunsemetinib from WHO Proposed list 125 of July 2021. This mapped to PubChem CID 86291496. The compound is claimed in Confluence Life Sciences' patent US9115089B2 as kinase inhibitor with potential to treat p38 kinase-mediated diseases [2]. Confluence Life Sciences is a subsidiary of Aclaris Therapeutics. We speculate that zunsemetinib is the MAPK-activated protein kinase 2 (MK2) inhibitor ATI-450 (formerly CDD-450 [3]), that is included on Aclaris' pipeline page. Phase 1 safety and tolerability of ATI-450 were reported in June 2021 [1]. This article described ATI-450 as an inhibitor of p38α/MK2 pathway-mediated inflammatory signalling, but discloses only a partial chemical structure in a supplementary figure. The same incomplete chemical structure appears in [3]. ATI-450 binds with high affinity to the interface of the p38MAPK-MK2 complex and selectively inhibits p38MAPK-catalysed phosphorylation of MK2 which stabilises the inactive conformation of MK2, and subsequently reduces inflammatory cytokine levels [3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 102.5
Molecular weight 513.14
XLogP 3.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Fc1cnc(c(c1)F)COc1cc(C)n(c(=O)c1Cl)c1cc(ncc1C)c1ccnc(n1)C(O)(C)C
Isomeric SMILES Cc1cc(OCc2ncc(F)cc2F)c(Cl)c(=O)n1c1cc(ncc1C)c1nc(ncc1)C(C)(C)O
InChI InChI=1S/C25H22ClF2N5O3/c1-13-10-30-18(17-5-6-29-24(32-17)25(3,4)35)9-20(13)33-14(2)7-21(22(26)23(33)34)36-12-19-16(28)8-15(27)11-31-19/h5-11,35H,12H2,1-4H3
InChI Key FQPQMJULRZINPV-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
ATI-450 is in active clinical development, for potential anti-inflammatory potential. It has also been investigated for potential to reduce inflammation in COVID-19 patients with moderate-severe disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04481685 A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19) Phase 2 Interventional University of Kansas Medical Center
NCT04247815 Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA Phase 2 Interventional Aclaris Therapeutics, Inc.
NCT04524858 Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Phase 2 Interventional Aclaris Therapeutics, Inc.